Emerging concepts in the management of the malignant haematological disorders

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 4, 2000, Pages 713-735

  Jønsson, Viggo ^a,b,c   Gemmell, Curtis G ^a,b,c   Wiik, Allan ^a,b,c  

^a Rigshospitalet   (Denmark)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

Chemotherapy; Immunotherapy; Leukaemia; Lymphomas; Supportive treatment

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

BLOOD DISEASE; BONE MARROW TRANSPLANTATION; ECONOMICS; GENE THERAPY; HUMAN; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; GENE THERAPY; HEMATOLOGIC NEOPLASMS; HUMANS; PALLIATIVE CARE;

EID: 0034189341     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.4.713     Document Type: Article

References (89)

1. Textbook of Malignant HaematQlogy. Degos L, Linch DC, Lövenberg B (Eds.), Martin Dunitz, London, UK U999):1-94.
2. HANDE KR: Principles and pharmacology of chemotherapy. In: Wintrobe's Clinical Hematology (Edition 10). Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM (Eds.), Williams & Wilkins, Baltimore, USA(1999):2077-2101.
3. VERWEIJ J, STOTER G: Principles of systemic therapy of cancer. In: Textbook of Medical Oncology. Cavalli F, Hansen HH, Kaye SB (Eds.), Martin Dunitz, London, UK (1997):23-10.
4. SKIPPER HE, SCHABEL FM, WILCOX WS: Experimental evaluation of potential anticancer agents X1U, on the criteria and kinetics associated with curability of experimental leukaemia. Cancer Chemotber. Rep. (1964) 34:1-24.
5. KALLIANPUR A: Supportive care in hématologic malignancies. In: Wintrobe's Clinical Hematology (Edition 10). Lee GR, Foerster J, Lukens J, Paraskevas F, Gréer JP, Rodgers GM (Eds.), Williams & Wilkins, Baltimore, USA (1999):2102-2156.
6. HUGHES WT, ARMSTRONG D, BODEY GP et al.: Consensus report: 1997 guidelines for the use of antimicrobial agents in ncutropcnic patients with unexplained fever, din. Infect. Dis. (1997) 25:551-573. A wide ranging review for dinial use.
7. VISCOLI C, CASTAGNOLA E: Planned progressive antimicrobial therapy in ncutropenic patients. Br. J. Haematol. (1998) 102:879-899.
8. KLASTERSKY J: Science and pragmatism in the treatment and prevention of ncutropenic infections.J. Antimicrob. Chemotber. (1998) (Suppl. D):13-24.
9. ANAISSIE EJ, VARTIVARIAN S, BODEY PG et al: Randomized comparison between antibiotics alone and antiblotics plus granulocyte-macrophagc colony stimulating factor (Escbericbla coli-delivered) in cancer patients with fever and neutropenia. Am. J. Med. (1995) 100:17-23.
10. LYMAN GH, KUDERE NM, BALDUCCI L: Economic impact of granulopoiesis simulating agents on the management of febril ncutropenia. Curr. Opin. Oncol. (1998) 10:291-296.
11. PAVLETIC ZS, BIERMAN PJ, ARMITAGE JO: Dose response and dose escalation. In: Textbook of Malignant Haematology. Degos L, Linch DC, Lövenberg B (Eds.), Martin Dunitz, London, UK (1999):281-298.
12. O'REILLY RJ, PAPADOPAULOS EB, SMALL TN. Allogeneic bone marrow transplantation. In: Textbook of Malignant Haematology. Degos L, Linch DC, Lövenberg B (Eds.), Martin Dunitz, London, UK (1999):315-381.
13. MCSWEENEY PA, STORE R: Mixed chimcrism: preclinical studies and clinical application. Biol. Bone Marmw Transplant. (1999) 5:192-203. An excellent paper within this field.
14. O'BRIEN S, KANTARJIAN HM, KOLLER C et al.: Sequential homoharringtonine and intcrferon-a in the treatment of early chronic phase chronic myelogcnous leukemia. Blood (1999) 93:4149-4153.
15. KANTARJIAN HM, O'BRIEN S, KEATING M et al.: Results of decltabine therapy in accelerated blastic phase of chronic myelogenous leukemia. Leukemia (1997) 11:1617-1620.
16. MCLAUGHLIN P, HAGEMEISTER FB, ROMAGUERA JE et al.: Fludarabinc, mitoxantrone and dcxamethasone, an effective new regime for indolent lymphoma trial. J.Clin. Oncol. (1996) 14:1262-1268.
17. BERNELL P, OHM L: Promising activity of gcmcitabine in refractory high-grade non-Hodgkin's lymphoma. Br.J. Haematol. (1998) 101:203-204.
18. AKAO Y, MIZOGUCHI H, KOJIMA S, NAOE T, OHISHI N, YAGI K: Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro, activation of caspascs and downregulation of bcl-2. Br. J. Haematol. (1998) 102:1055-1060.
19. MAK1 A, DIWAKARAN H, REDMAN B et al.: The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolostatin in human diffuse large cell h/mphoma. Anti-Cancer Drug (1995) 6:392-397.
20. WANG H, CHOW DA: Protein kinase C expression links natural antibody binding with surveillance of activated and preneoplastic cells. Scand. J. Immunol. (1999) 49:381-390.
21. WANG Q, FAN S, EASTMAN A, WORLAND PJ, SAUSVILLE EA, O'CONNOR PM: UCN-01, a potent abrogator of QJ checkpoint function in cancer cells with disrupted p53./ Natl. Cancer Inst. (1996) 17:956-965.
22. BYRD JC, SHINN C, WASELENKO JK et al.: Flavopiridol induces apoptosisin chronic lymphocytic leukaemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53 Blood (1998) 92:3804-3816.
23. SENDEROWICZ AM. Cyclin-dependent kinasc modula, tors as novel therapeutic approaches for hematological malignancies. In: American Society of Hematohgy Education Program Book. Schechter GP, Huffman R, Schrier SL, Bajus JL (Eds.), Am. Soc. Hematol. Soc., New Orleans, Washington DC, USA (1999):454-462.
24. SHINN C, BYRD JC, RAJI R et al.: Depsipeptidcs is selectively cytotoxic toward human chronic lymphocytic leukemia cells and favorably alters the bcl-2:BAX ratio and p27 expression with concomitant cleavage of caspase 3. Blood (1998) 90:103a. Abstract 422.
25. D'AMORE RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J: Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA (1994) 91:4082-4085.
26. KNELLER R, RAANANI P, HARDAN I et al.: Therapy with thalidomide in refractory multiple myeloma patients, the revival of on old drug. Br. J. Haematol. (2000) 108:391-393.
27. SYKES M, SZOT GL, SWENSON KA, PEARSON DA: Induction of high levels of allogcncric hcmotopoictic reconstitution and donor-specific tolerance -without myelosuppressivc conditioning. Nature Med. (1997) 3:783-787.
28. KHOURI IF, KEATING M, KÖRBLING M et al.: Transplantlite: induction of graft-rersis-malignancy using fludarabine-based nonablative chemotherapy and allogeneric blood progenitor-cell transplantation as treatment for lymphoid malignancy. J. Clin. Oncol. (1998) 16:2817-2824.
29. SLAVIN S, NAGLER A, NAPARSTEK E et al.: Nonmyeloablativ stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytorcduction for treatment of malignant and nonmalignant hématologie diseases. Blood (.1998) 91:756-763.
30. Appropriate uses of human immunoglobulin in clinical practice: memorandum from IUIS/WHO meeting. WHO Bull. (1982) 60:43-47.
31. AVRAMEREAS S, TERNYNCK T: The natural autoantibodics system: between hypothesis and facts. Mol. Immunol. (1993) 30:1133-1142.
32. This review article provides an excellent summary. 32. REICHUN M: Autoantibodies to ubiquitous intraccllular antigens interact with living cells. Immimologist (1998) 6:76-78.
33. KAVERI SV, LACROIX-DESMAZES S, MOUTHON L, KAZATCHKINE MD: Human natural autoantibodics: lessons from physiology and prospects for therapyImmunologist (1998) 6:227-233.
34. OCHSENBEIN AF, FEHR T, LUTZ C et ah Control of early viral and bacterial distribution and disease by natural antibodies. Science (1999) 286:2156-2159.
35. MEISSNER HC, SCHLIEVERT PM, LEUNG DYM: Mechanisms of inununoglobulin action: observations in Kawasaki syndrome andRSV prophylaxis. Immttnol. Rev. (1994) 139:109-123.
36. YU Z, LENNON VA: Mechanism of iv. immune globulin therapy in antibody-mediated autoimmune disease. N. Engl.J. Med. (1999) 340:227-228.
37. SHOENFELD Y, FISHMAN P. v-globulin inhibits tumour spread in mice. Int. Immunol. (1999) 11:1247-1252.
38. PRASAD NKA, PAPOFF G, ZEUNER A et al.: Therapeutic preparations of normal poryspecific IgG (WIG) induce apoptosis hi human lymphocytes and monocytcs, a novel mechanism of action of WIG involving the Fas apoptotic pathway./ Immunol. (1998) 161:3781-3790. A dear and comprehensive review.
39. VIARD I, WEHRIL P, BULLANI R et ah Inhibition of toxic epidermal necrolysis by blockade of CD95 with human iv. inimunoglobulin. Science(1998) 282:490-493.
40. LUNDIN J, OSTERBORG A, BRITTINGER G et al.: Campath-lH monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's malignant lymphomas: a Phase II multicenter study. J. Clin. Oncol. (1998) 16:3257-3263
41. DAVIS TA, MALONEY DG, CZERWINSKI DK et al.: Anti-idiotype antibodies can induce long-term complete remission in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood (1998) 92:1184-1190. This excellent paper reports data from clinical use.
42. MALLONEY DG, GRILLO-LOPEZ AJ, WHITE CA et al: IDEC-C2B8 (Rituximab) antiCD20 monoclonal antibody therapy In patients with relapsed low grade non-Hodgkin's lymphoma. Blood (1997) 90:2188-2195.
43. BERINSTEIN NL, GRILLO-LOPEZ AJ, WHITE CA et al: Association of serum Rctuximab (IDEC-C2B8) concentration and antitumour response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. (1998) 9:995-1001.
44. COIFFIER B, HAIOUN C, KETTERER N et ah Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase n study. Blood (1998) 92:1927-1932.
45. BRYD JC, WASELENKOJK, MANEATISTJ et ah Rituximab therapy hi hématologie malignancy patients with circulating blood tumour cells: association with increased infusion-related side effects and rapid blood tumour clearance./ Clin. Oncol. (1999) 17:791-795.
46. CZUCZMAN MS, GRILLO-LOPEZ AJ, WHITE CA et al.: Treatment of patients with low-grade B-cell lymhomas with the combination of chimeric antiCD20 monoclonal antibody and CHOP chemotherapy. J Clin. Oncol. (1999) 17:268-276.
47. NGUYEN DT, AMESS JA, DOUGHTY H, HENDRY L, DIAMOND LW: IDEC-C2B8 antiCD20 (Rituximab) immunothcrapy In patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of 48 patients. Etir. J. Haematol. (1999) 62:76-82.
48. STONE MJ, SAUSVILLE EA, FAY J\V et al.: A Phase I study of bolus versus continuous infusion of antiCD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. B/oorf(1996) 88:1188-1197.
49. MULTAN1 PS, OTJAY S, NADLER LM, GROSSBARD ML: Phase U clinical trial of bolus infusion of antiB4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin. Cancer Res. (1998) 4:2599-2604.
50. GROSSBARD ML, N1EDZWIECKI J, NADLER LM et at.: AiitiBi blocked ricin (anti-B4bR) adjuvant therapy post autologous bone marrow transplantation: a Phase III intergroup study. Proc. ASCCX.1998) 17:3a.
51. KAMINSK1 MS, ZASADNY KR, FRANCIS I et al.: Iodine-131 antiBl radioimmunotherapy for B-cell lymphomas. J. Qin. Oncol. (1996) 14:1974-1981.
52. DEB N, GORIS M, TRISLER K et al.: Treatment of hormone-refractory prostate cancer with 90Y-YT-356 monoclonal antibody. Clin. Cancer Res. (1996) 2:1289-1297.
53. JUWEID M, SHARKEY R, MARLOWITZ A et al.: Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric or humanized LL2, an antiCD22 monoclonal anübody. Cancer Res. (1995) 55:5899s5907s.
54. WHITE C, HALPERN S, PARKER B et at.-. Radioimmunotherapy of relapsed B-cell lymphoma with Yttrium-90 anti-idiotype monoclonal antibodies. Blood (1996) 87:3640-3647.
55. STEVENSON FK: Vaccine strategies in indolent lymphomas. In: American Society of Hematology Education Program Book. Schechter GP, Hoffman R, Schrier SL, Bajus JL (Eds.), Am. Soc. Hematol. Soc., New Orleans, Washington DC, USA (1999):312-318.
56. SHERR C: Cancer cell cycles. Science (1996) 274:1672.
57. ISAACSON PG: Recent developments in our understanding of gastric lymphomas. Am. J. Surg. Palhol. (1999) 20:51-7. The best review within this field to date.
58. COLLINS RD: Is clonality equivalent to malignancy: specifically, is immunoglobulin gene rearrangement diagnostic of malignant lymphoma? Hum. Patbol. (1997) 28:757-759.
59. ANDERSON WF: Human gene therapy. Nature (1998) 392:25-27.
60. WIVEL NA, WILSON JM: Methods of gene delivery. Hematol. Oncol. Clin. North Am. (1998) 12:483-501.
61. BOUVET M, ELLIS LM, N1SHIZAKI M et al.: Adenovirus mediated wild type p53 gene transfer downrcgulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res. (1998) 58:2288-2292.
62. ROTH JA, SWISHER SO, BOUVET M, MERRITT JA: p53 gene replacement therapy in lung cancer. Adv. Oncol.(1998) 14:3-7.
63. DIBER MS, ABEDI MR, BJÖRKSTRAND B et ah. Suicide gene therapy for plasma cell tumours. Blood (1996) 88:2192-2200.
64. TIBERGHIEN P: Suicide gene for control of graft-versus-host disease. Curr. Opin. Hematol. (1998) 5:478-482.
65. BONINI C, BORDIGNON C: Suicide gene therapy for control of graft-rersus-host disease. Immunologist (1999) 7:93-96. An excellent description of the technique.
66. HO PTC, PARKINSON DR: Antisense oligonucleotides as therapeutics for malignant diseases. Semin. Oncol. (1997) 24:1-17.
67. VAERMAN JL, MOUREAU P, DELDIME F et al.: Antisense oligodeoxyribinucleotides suppress hématologie cell growth through stepwise release of deoxyribinucleotides. Blood (1997) 90:331-339.
68. KRONENWETT R, STEILD U, KIRCH M, SCZAKIEL G, HASS R: Oligodeoxyribonucleotidc uptake in primary human hematopoictic cells is enhanced by cat ionic lipids and depends on the hematopoietic cell subset. Blood (1998) 91:852-862.
69. ALBRECHT T, SCHWALB R, HENKES M et ah Primary proliferating immature myeloid cells from CM L patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal. Br. J. Haematol. (1996) 95:501-507.
70. BHATIA R, VERFAILLIE CM: Inhibition of BCR-abl expression with antiscnse oligodeoxynucleotides restores β-1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors. Blood (.1998) 91:3414-3422.
71. LOWENBERG B, DOWNING JR, BURNETT A: Medical progress: acute myeloid leukemia, ff. Engl.J. Med. (1999) 341:1051-1062.
72. MENDOZA RB, CANTWELL MJ, KIPPS TJ. Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization. J. Immunol. (1997) 159:5777-5781.
73. KATO K, CANTWELL MJ, SHARMA S, KIPPS TJ: Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia. J. Clin. Invest. (1998) 101:1133-1141.
74. DU MQ, XU CF, DISS TC, PENG HZ, WOTHERSPOON AC, ISAACSON PG: Intestinal dissemination of gastric mucosa associated lymphoid tissue-lymphoma. Blood (1996) 88:4445-451.
75. ZUCCA E, BERTONI F, ROGGERO E et ah Molecular analysis of the progression from Helicobacter pyloriassociated chronic gastritis to mucosa-associated lymphoid-tissuc lymphoma of the stomach. N. Engl.J. Med. (1998) 338:804-810.
76. APPELMELK BJ, FALLER G, CLAEYS D, KIRCHNER T, WANDENBRUCKE-GRAULS CMJE: Bugs on trial, the case of Helfcobacter pylori and autoimmunity. Immtinol. Today (1998) 19: 296-299.
77. J0NSSON V, WIIK A, HOU-JENSEN K étal.: Autoimmunity and extranodal lymphocytic infiltrates in lymphoproliferative disorders./ Intern. Med. (1999) 245:277-286.
78. ROLSTON KV, BERKEY P, BODEY GP et ah. Acomparison of imipencm to ccftazidimc with or without amlkacia as empiric therapy in febrile neutropenic patients. Arch. Intern. Med. (1992) 152:283-291.
79. BODEY GP: Empirical antibiotic therapy for fever in neutropenic patients. Clin. Infect. Dis. (1993) 17(Suppl. 2):S378-384.
80. KLASTERSKY J, CAPPEL R, DANEAU D: Clinical significance of in vitro synergism between combination antibiotics in Gram-negative infections. Antimlcrob. Agent Cbemother. (1972) 2:470-475.
81. KERN WV FOR THE INTERNATIONAL ANTIMICROBIAL THERAPY COOPRATIVE GROUP OF EORTC: Oral versus iv. empirical therapy for fever in cancer patients with an expected short duration of granulocytopenia. Proc. ICAACW9S). Abstract 18.
82. WALSH TJ, FINBERG RW, ARNDT C et ah liposomal amphotericin B for empiric therapy in patients with persisting fever and ncutropenia. National Institute of Allergy and Infectious diseases Mycosis study group. M Engl.J. Med. (1999) 340:764-771.
83. WINGARD JR: Prevention and management of invasive fungal infections. In: American Society of Hematology Education Program Book. Schechter GP, Hoffman R, Schrier SL, Bajus JL (Eds.), Am. Soc. Hematol. Soc., New Orleans, Washington DC, USA (1999)033-535.
84. WILLIAMS C, COYLE D, GRAYJ etal.: European School of Oncology advisory report to the Commission of the European Communities for 'Europe against cancer programme' cost-effectiveness in cancer care. EUT. J. OJcer(1995) 31:1410-1424.
85. DRUMMOND MF. Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status? Health Econ. (1992) 1:85-92.
86. KLASTERSKY J: Current attitudes for therapy of febrile ncutropenia with consideration to cost-effectiveness.Curr. Opln. Oncol. (1998) 10:284-290. This is an update of the previous study of the author.
87. J0NSSON V, M0RK HANSEN M, LJUNGMAN P, KAASA S: Pharmacoeconomic considerations in treating patients with acute leukaemia. PhannacoEconomics (1999) 15:167-178.
88. TORRANCE GW: Designing and conduction cost-utility analysis. In: Quality of life and Phannacoeconomics in Clinical Trials. Spilker B (Ed.), Lippincott-Raven, Philadelphia, USA (1996):1105-1111.
89. PAYERS PM, HAND DJ: Generalisation from Phase III clinical trials: survival, quality of life and health economics. Lancet (1997) 350:1025-1027.